Navigation Links
Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
Date:3/16/2009

ntellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2008. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.

                        Poniard Pharmaceuticals, Inc.
               Condensed Consolidated Statements of Operations
                    (In thousands, except per share data)
                                 (Unaudited)

                                      Three Months       Twelve Months
                                         Ended               Ended
                                      December 31,        December 31,
                                     ------------        -------------
                                      2008     2007      2008      2007
                                      ----     ----      ----      ----

    Revenues                            $-       $-        $-        $-
                                       ---      ---       ---       ---
    Operating expenses:
      Research and development      10,203    7,011    34,714  
'/>"/>
SOURCE  Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)...  Decision Resources, one of the world,s leading ... issues, finds that, for the treatment of rheumatoid ... rheumatologists cite a therapy,s induction of remission as ... prescribing decisions. Over 60 percent and 70 percent ... percentage of patients achieving remission at six months ...
(Date:6/19/2013)... N.Y. , June 19, 2013 ... sourcing company servicing all branches of government from ... they have expanded their facilities to include complex ... designed and fabricated some very complex aluminum parts ... continue to expand our capabilities to service government ...
(Date:6/19/2013)... 2013 /PRNewswire-iReach/ -- Today leading web researchers Change Sciences ... Pharmaceutical web sites for usability, engagement, and conversion. The ... platform, which compares how people experience sites with competitors ... The top three performers are easier to use, ... bottom performers have usability problems, lack aspects of design ...
Breaking Medicine Technology:U.S. and European Rheumatologists Agree That a Therapy's Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis 2Amerivet Solutions Expands to Manufacture Complex Metal Designs 2Sunovion tops new Change Sciences User Experience Rankings for Pharmaceutical Industry while McNeil-PPC ranks worst overall 2
... ATLANTA, Nov. 11, 2010 Arbor Pharmaceuticals, a specialty ... completion of a $34.8 million financing.  This financing included ... B Preferred Stock led by Signet Healthcare Partners, LLC. ... of a term loan provided by several of the ...
... Nov. 11, 2010 According to Millennium Research Group (MRG), ... European PACS, RIS, and CVIS market is largely a replacement ... five years in the United Kingdom and France. ... Services (NHS) Radiology IT Project in 2013 presents a large ...
Cached Medicine Technology:Arbor Pharmaceuticals Completes $34.8 Million Financing 2Arbor Pharmaceuticals Completes $34.8 Million Financing 3European PACS Market To Attain $512M by 2015 2
(Date:6/20/2013)... During a June 13 panel discussion on ... Health Benefit Exchange confirmed the existence of the Federal ... industry consider,” writes panel moderator Steve Davis in a ... unicorns and leprechauns.” , “We are the only state ... Hub live,” Rebecca Pearce told attendees at Gorman Health ...
(Date:6/20/2013)... Mobile, a leading manufacturer and distributor of wholesale-direct-to-consumer ... of 16GB version of the Mini Studio Android tablet. ... tablet that is a direct competitor to the iPad ... it will be launched at promotional price at $121 ... Mini STUDIO is part of the Handgiftbox.com “STUDIO Series,” ...
(Date:6/20/2013)... Emotional abuse expert and author, Lisa Kroulik, has ... used by emotional abusers. In the book, she ... spoken to for days, being blamed for everything, and ... and more in her marriage to an emotionally abusive ... years because she did not realize her ex-husband's behavior ...
(Date:6/20/2013)... Bournemouth, Dorset (PRWEB) June 20, 2013 ... disease) and more serious medical conditions because they do ... of Eludril mouthwash and Elgydium toothpaste. , Seven million ... leaving it 48 hours between brushes, latest data from ... per cent of people polled by the BDHF also ...
(Date:6/20/2013)... CT (PRWEB) June 20, 2013 Startups ... to energize their sales or test new markets, and ... U.S. now have a new sales outsourcing ... sustained sales revenue. , Strategy Sales Partners ... professionals. Founded by business owners for business owners, Strategy ...
Breaking Medicine News(10 mins):Health News:Federal Data Services Hub Does Exist, AISHealth.com Blog Post Reports 2Health News:Android Tablet PC Mini Studio with Android 4.1 with 16GB is Here at $121 Only at Handgiftbox.com 2Health News:Lisa Kroulik Empowers Women to Recognize Emotional Abuse in Intimate Relationships 2Health News:Millions Are Risking Gum Disease, Warn Eludril And Elgydium 2Health News:Millions Are Risking Gum Disease, Warn Eludril And Elgydium 3Health News:Strategy Sales Partners Launches to Provide Sales Outsourcing Assistance to Businesses 2Health News:Strategy Sales Partners Launches to Provide Sales Outsourcing Assistance to Businesses 3
... SPRING, Md., Feb. 28 Celebrity chef Emeril,Lagasse joins ... top,quality food with viewers this summer in the new ... 24/7 eco-lifestyle,television network, is set to launch in June ... premiering throughout the summer, including,EMERIL GREEN (wt) which will ...
... TDP-43 mutations expose potential therapeutic target, experts say , , ... a new, yet rare, genetic mutation in the development ... only exposes a potential therapeutic target for treating the ... mutation sets in motion the mechanism that causes many ...
... and men are completely satisfied with the time they spend ... study published in the Journal of Family Issues. , ... be more time pressured than those who work part time ... professor of sociology at Kent State University. , In ...
... will Integrate IDC,s X1590 into the First Standardized ... ... /PRNewswire-FirstCall/ - IDC (Imaging Dynamics Company,Ltd.) (TSX: IDL), the global ... announced that Halifax Biomedical has selected,IDC,s X1590 as the DR ...
... PRINCETON, N.J., Feb. 28 Organizations,representing the state,s ... funding cuts proposed for hospital care for New ... $33 billion state spending plan for 2009, released,Tuesday, ... with funding of $608,million compared with current funding ...
... unlocked some of the mysteries of how the developing ... A present in the maternal blood stream. Their results ... Journal of Biological Chemistry. , The researchers studied ... formation of vitamin A stores in the body, during ...
Cached Medicine News:Health News:Emeril Lagasse and Planet Green Partner with Whole Foods Market(R) on Innovative New Series 2Health News:Emeril Lagasse and Planet Green Partner with Whole Foods Market(R) on Innovative New Series 3Health News:New Gene for Lou Gehrig's Disease Identified 2Health News:New Gene for Lou Gehrig's Disease Identified 3Health News:IDC X-Series DR system selected for use in leading edge RSA clinical trial application 2Health News:IDC X-Series DR system selected for use in leading edge RSA clinical trial application 3Health News:Hospital Groups United in Opposition to Charity Care Cuts 2Health News:Rutgers researchers unlock mysteries of vitamin A metabolism during embryonic development 2Health News:Rutgers researchers unlock mysteries of vitamin A metabolism during embryonic development 3